BTK inhibition in experimental autoimmune diseases in preclinical models results in reduced disease activity, notably in mouse models of collagen-induced arthritis and anti-glomerular basement membrane glomerulonephritis, while increased BTK expression and phosphorylation in patients with systemic autoimmune disease correlated with autoantibody production [74,76]. This evidence concerns the gene BTK and autoimmune disease.